Core Viewpoint - The company expects a significant increase in net profit for the year 2025, with projections ranging from 110 million to 138 million yuan, representing a year-on-year growth of 36.93% to 71.78% [2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The profit forecast is based on preliminary calculations by the company's finance department and has not yet been audited by an external accounting firm [1][2]. Group 2: Reasons for Performance Change - The expected increase in net profit is attributed to a reduction in R&D expenses compared to the previous year, primarily due to fewer new projects in generic drug development and delays in the internal approval process for a strategic cooperation agreement with a partner company [2]. - Despite a significant decline in sales volume for certain products due to low demand and price drops, the company's formulation business has seen rapid growth driven by new product launches and successful bidding in centralized procurement [2].

Core Insights - The company announced that it has not yet utilized AI methods in the production process of raw materials [2] - The establishment of Jinhe Bio in 2023 aims to apply synthetic biology in the production of raw materials [2] - The company has achieved full enzyme-based production processes for cephalosporin raw materials, leading to cost reduction and efficiency improvement [2] - In preliminary research for penicillin raw materials, Jinhe Bio has completed enzyme process validation for products like amoxicillin and has developed the capability for independent enzyme preparation [2]